Published Time：

Respiratory diseases are the second leading cause of death globally. In China, the mortality rate is 68 per 100,000, ranking after cardiovascular and cerebrovascular diseases and cancer, making it the third leading cause of chronic disease death among Chinese residents. In recent years, market data shows a yearly increase in respiratory diseases due to factors such as an aging population, smoking, air pollution, and new and drug-resistant pathogens.

  The respiratory system market has high concentration; foreign companies such as GSK, Boehringer Ingelheim, Merck, Novartis, AstraZeneca, and Johnson & Johnson have occupied the market for many years; among domestic companies, Wanquan Technology Pharmaceutical, Shanghai Pharmaceuticals, Hengrui, and Lunan are among the top players; HealthGen, with its professional and highly specialized team focusing on this field, has also gradually gained market attention due to the rapid progress of its drug development.

Respiratory inhalers show huge market potential, with domestic and foreign companies competing to establish a presence.

According to the 2017 global drug sales rankings, the global respiratory drug industry shows overall stable development. The global market for respiratory disease drugs exceeds US\$20 billion and is growing at an annual rate of 2.4%. According to data from CMH, in 2017, the domestic respiratory drug market reached 143.154 billion yuan, a year-on-year increase of 4.23%. Among them, the anti-asthma drug market reached 24.131 billion yuan, a year-on-year increase of 4.86%.

Anti-asthma inhalers are one of the important products in the treatment market. In 2017, domestic anti-asthma inhaler use exceeded 10 billion yuan, reaching a scale of 10.605 billion yuan, accounting for 7.41% of the overall respiratory drug market. Among them, the sales of budesonide were the most eye-catching; in 2017, the global budesonide sales market was US\$1.176 billion, a year-on-year increase of 10.84%; in 2017, the domestic budesonide market share reached 46.9%, a year-on-year increase of 18.04%.

In the competition in the domestic respiratory market, foreign companies AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim occupy a large market share; domestic companies such as Zhengda Tianqing, Lunan Pharmaceutical, and Hengrui also have rich respiratory drug product systems. HealthGen has made significant inroads into the respiratory drug market in recent years, and many of its related products have made significant progress. Currently, HealthGen's professional team adheres to its unique and innovative R\&D technology platforms, including antibody technology platform, microsphere sustained-release technology platform, and respiratory administration technology platform, focusing on anti-tumor, gonadotropin, digestive, neurological, and respiratory treatment areas, forming a relatively focused and clear product R\&D pipeline.

Previously, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) announced the "List of Drug Registration Applications to be Included in the Priority Review Procedure (29th Batch)", publicizing the drug registrations to be given priority review and their applicants. According to the announcement, the levosalbutamol hydrochloride inhalation solution submitted by Shenzhen Tai Tai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of HealthGen, and Shanghai Fanyu Health Pharmaceutical Technology Co., Ltd., a holding subsidiary, and the salmeterol fluticasone inhalation powder submitted by Shenzhen Haibin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of HealthGen, were included in the list. This gives HealthGen a head start in the inhaler market, which will help to promote the rapid filling of the domestic gap in the research and development of related drugs. The company continues to actively carry out R\&D work, deploying research on various drug categories that meet market demand, thereby achieving multi-faceted development across its various industrial chains.

Significant achievements in industry-academia-research collaboration; professional teams may receive capital support.

In order to seize the development opportunities in the respiratory drug market, HealthGen has conducted in-depth research on respiratory drugs, establishing Shanghai Fanyu Health Pharmaceutical Technology Co., Ltd., with Professor Jin Fang, a member of the Chinese Pharmacopoeia Commission and former director of the Shanghai Respiratory Drug Engineering and Technology Research Center of the Shanghai Institute of Pharmaceutical Industry, at its core. It also jointly established Guangzhou HealthGen Respiratory Drug Engineering and Technology Co., Ltd. with the Guangzhou Institute of Respiratory Diseases, headed by Academician Zhong Nanshan of the Chinese Academy of Engineering, a leading expert in respiratory diseases and a medical authority, investing heavily in the R\&D of respiratory drugs. By the end of last year, HealthGen had more than 20 respiratory drug projects under development, including 18 pre-clinical research projects, 4 projects submitted for registration and under review, 1 project in the clinical research stage, and 2 projects that have completed clinical research and applied for production. Among them, 9 projects were selected last year for support under the "Major New Drug Creation" national major science and technology project in the field of high-end preparations.

Among them, ipratropium bromide aerosol and budesonide aerosol have made rapid progress, and have completed clinical trials and applied for production. Tobramycin inhalation solution has obtained clinical approval; combination ipratropium bromide inhalation solution, budesonide suspension for inhalation, levosalbutamol inhalation solution, and salmeterol fluticasone inhalation powder have been submitted for registration. HealthGen expects to continue to promote the market launch of related drugs in the future, bringing more treatment options to the respiratory preparation market.

The high incidence rate makes respiratory drugs considered one of the most promising drug markets in the future. According to data from Prospective Industry Research Institute, although the respiratory drug market is expanding rapidly, compared with systemic anti-infectives, anti-tumor drugs, immunomodulatory drugs, and consumer channels and metabolism, the scale of respiratory drugs is still relatively small, accounting for only 3.39% in 2017. The huge future growth potential is evident. While HealthGen's respiratory drug products are rapidly being launched, two major products—budesonide series and ipratropium bromide series—will quickly fill the gaps in the respiratory drug market.

  Today, leveraging the advantages of combining industrial and capital operations, HealthGen's share placement is proceeding in an orderly manner. The implementation of the Zhuhai Greater Bay Area health industry base construction project and the Haibin Pharmaceutical Ping Shan pharmaceutical industrialization base project will provide strong support for the production of the company's key products in the future, creating more new profit points for HealthGen on the basis of further enhanced scientific research strength, improving the company's overall competitiveness in the pharmaceutical market, and enabling the company's industry to achieve leapfrog development driven by capital.